Initial results from dose escalation of a phase 1/2 first-in-human, open label study of AU-007, a monoclonal antibody that binds to IL-2 and prevents its binding to CD25, in patients with solid tumors

AU-007 - Aulos Biosci

https://jitc.bmj.com/content/10/Suppl_2/A805

James Vasselli 1; Paul de Souza 2; Sophia Frentzas 3; Andrew Weickhardt 4; Timothy Wyant 1; Jenny Tang 1; Lori Richards 5; Aron Knickerbocker 1; Inbar Amit 6; Yanay Ofran 6

Oct 6, 2022